You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
華東醫藥(000963.SZ):司美格魯肽注射液糖尿病適應症已完成III期臨牀研究全部受試者入組,預計2024年Q4獲得主要終點數據並遞交pre-BLA溝通
格隆匯 11-18 09:09

格隆匯11月18日丨華東醫藥(000963.SZ)11月18日在投資者互動平台表示,公司自主研發的口服小分子GLP-1受體激動劑HDM1002,已於2024年10月獲得體重管理適應症II期臨牀研究的頂線結果,計劃2024年Q4遞交pre-III期溝通申請,並預計在2025年Q1開展體重管理適應症臨牀III期試驗。 司美格魯肽注射液糖尿病適應症已完成III期臨牀研究全部受試者入組,預計2024年Q4獲得主要終點數據並遞交pre-BLA溝通。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account